NEW YORK (TheStreet) -- Shares of Panera Bread  (PNRA) rose slightly on Wednesday, after Credit Suisse initiated coverage of the stock with an outperform rating and $190 price target. 

The stock was recently up 72 cents to $157.87.

Also, Credit Suisse initiated Buffalo Wild Wings (BWLD) with an underperform rating. 

This call is intriguing, because Panera has been so disappointing and Buffalo Wild Wings has done so well, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment. 

If Panera "can get it together," the stock can go up "very big," he said. Cramer said the company needs to complete its Panera 2.0 initiatives, be successful with its natural and organic products, and solve issues with the ordering process at its restaurants.

If the company can complete those three tasks, the stock is a buy. However, buying it now seems to be a little early, Cramer said. 

Buffalo Wild Wings BWLD and Panera Bread Company PNRA data by YCharts

Turning his attention to Regeneron (REGN) - Get Report, Cramer is optimistic that the data for the company's anti-cholesterol drug will be positive when they are released this weekend. 

Amgen (AMGN) - Get Report is making a competitive product, but it's not as good as Regeneron's, Cramer said. 

Regeneron's treatment will become the standard for patients who can't take or aren't seeing good enough results from their current cholesterol medications. According to Deutsche Bank, that could be a $17 billion market, Cramer concluded. 

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.